Comparing the Impact of Dorzolamide Vs. Netarsudil on IOP & Ocular Perfusion in Early Glaucoma

calendar
23 Sep, 25

Introduction

Glaucoma is a neurodegenerative disease involving both structural and functional changes. Optical tomography angiography (OCTA) studies have indicated the susceptibility of superficial vessels such as the radial peripapillary capillaries to glaucomatous damage. Exploring the role of netarsudil and dorzolamide in improving the optic disc and macular perfusion may provide important insights for treatment of these patients.

Aim

To compare the impact of netarsudil and dorzolamide on macular and optic nerve head (ONH) perfusion changes on OCTA, and macular ganglion cell layer (mGCL) and peripapillary retinal nerve fiber layer (pRNFL) thickness on OCT in preperimetric/early glaucoma patients.

Patient Profile

  • Patients with preperimetric/early open glaucoma eyes (N= 80, age ≥40 years)

Methods

Study Design

  • A prospective, randomized, parallel group, active controlled trial. 

Treatment Strategy

  • Patients were randomized as follows:
    1. Group I: Netarsudil 0.02% (45 eyes) 
    2. Group 2: Dorzolamide 2% (45 eyes)

Outcomes

  • Change in macular and ONH perfusion
  • Change in intraocular pressure (IOP)

Assessments

  • The IOP, ONH perfusion, ONH flux index (FI) and macular vessel density (mVD) were evaluated on OCTA at baseline, 4 months, 8 months, and 12 months.
  • The pRNFL thickness and mGCL thickness were evaluated on OCT at baseline, 4 months, 8 months, and 12 months.

Results

  • The mean baseline IOP in groups 1 and 2 was 19.52 mmHg and 19.5 mmHg, respectively. 
  • At 12 months, patients in group 1 had a decrease of 2.77mmHg (14.19%) in IOP, as compared to 1.85 mmHg (9.48%) in group 2 (Fig. 1).

Fig. 1: Change in IOP at 12 months

image

  • Group 1 showed 1.03% increase in ONH perfusion (p<0.001) while group 2 showed 1.16% increase in ONH perfusion (p<0.001). The ONH perfusion did not differ significantly between the two groups at 4, 8 and 12 months (Table 1). 

Table 1: Changes in ONH perfusion 

Parameter

Baseline

12 Months

Difference

P value

Netarsudil 

43.45

44.57

+1.03

<0.001

Dorzolamide

42.96

44.12

+1.16

<0.001

  • The mVD increased by 1.58 mm/mm2 (12.32 at baseline vs. 13.9 mm/mm2 at 12 months) and ONH FI increased by 0.03 at 12 months in group 1. But such a trend was not observed in group 2 for mVD or ONH FI.
  • As per the OCT findings, pRNFL and mGCL showed normal variability in both the groups. 
  • Congestion (40%) was the most common adverse event observed in the netarsudil group. Metallic taste (42.5%) was the most common adverse event observed in the dorzolamide group.
  • The incidence of adverse events was comparable for both the medications (p=0.65).

Conclusions

  • Amongst patients with preperimetric/early glaucoma, treatment with netarsudil led to increase in all the OCTA parameters including mVD, ONH perfusion, and ONH FI. 
  • Treatment with dorzolamide was also associated with an increase in ONH perfusion. 
  • Netarsudil monotherapy also resulted in a higher decrease in IOP as compared to dorzolamide therapy.

J Glaucoma. 2025 Jul 29 (Online ahead of print) Doi: 10.1097/IJG.0000000000002615.